Growing Prevalence of Breast Cancer in China Fuels Medical Need for Lymphatica's Implantable Lymphedema Treatment

What medical need does Lymphatica Medtech treat?

We are developing innovative medical devices to treat lymphatic diseases. Our focus is on chronic lymphedema, an incurable swelling of the limbs that affects 140 million people worldwide – including a quarter of breast-cancer survivors. We estimate it to be a $4.7-billion market. Our first product, LymphoDrain, will be the first implantable medical device for long-term lymphedema treatment. Our thumb-sized, wearable device will give patients an unmatched improvement in quality of life, and lower their risk of infections.

 

How important is it to be in China?

Class III medical devices are a global business, so to compete we need to internationalize early. There's also a clear clinical need for our product in China: six million people suffer from chronic lymphedema, and this number is rapidly increasing as incidences of breast cancer grow.

 

What are your goals of the Venture Leaders China roadshows?

My main objectives are to gain a deeper understanding of Chinese medical device businesses, the sector's opportunities and its constraints. I want to identifying distributors and hospitals with the potential to become business and clinical partners. I'm also looking to establish strong contacts within China's investment community.

 

Venture Leaders China 2019 is co-organised by Venturelab and swissnex China, and supported by: digitalswitzerland, EPF Lausanne, ETH Zurich, Gebert Rüf Stiftung, Canton Vaud, VISCHER, and Canton Zurich.

Venture Leaders China 2019 winners